-- 周二下午晚些时候，医疗保健类股小幅走高，纽约证券交易所医疗保健指数和道富医疗保健精选行业SPDR ETF (XLV) 均上涨约0.4%。 iShares生物技术ETF (IBB) 上涨0.1%。 公司新闻方面，Edgewise Therapeutics (EWTX) 股价飙升22%，此前Wedbush将该公司目标股价从32美元上调至46美元，并维持“跑赢大盘”评级。 辉瑞 (PFE) 第一季度业绩超出分析师预期，其主要品牌强劲的需求抵消了新冠肺炎产品销售疲软的影响。辉瑞股价上涨0.9%。 默克 (MRK) 股价上涨0.6%。该公司周二表示，已完成对Terns Pharmaceuticals的收购，收购价格为每股53美元。 Scilex (SCLX) 股价周二下跌 3%，此前该公司表示，其子公司 ACEA Therapeutics 同意以 10 亿美元的全股票交易将 ACEA Pharma 的 100% 股权转让给 Phoenix Asia (PHOE)。
Related Articles
Asia
Cofoe Medical Technology Nets HK$1 Billion From Hong Kong IPO Ahead of Debut
Cofoe Medical Technology (HKG:1187, SHE:301087) raised HK$1.01 billion in net proceeds from its initial public offering in Hong Kong.The offer price was set at HK$39.33 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based home care medical device provider offered 27 million H-shares in the global offering.The Hong Kong public offer was 399.08 times subscribed, with 2.7 million shares allocated, representing 10% of the total offering.The international offering was 3.4 times subscribed, with 24.3 million shares allocated, accounting for 90% of the total offering.Cornerstone investors, including Lens Technology (HK), Changsha Yufeng Technology, Vision Capital, and Panjing Harbourview Investment Fund, were allocated about 9.7 million shares in the international tranche, according to the filing.Cofoe Medical is scheduled to begin trading in Hong Kong on Wednesday, May 6.
$HKG:1187$SHE:301087
Insider Trading
Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml
$CYTK
Mining & Metals
Correction: -- Pan American Silver Targets Up to US$1B in Shareholder Returns in 2026 Through Enhanced Shareholder Return Framework
$PAAS.TO